Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT01403025
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm

Study Details

This trial is conducted in Asia. The aim of the trial is to assess the incidence rate and type of SADRs (serious adverse drug reactions).

Key Dates

Start date
Jul 19, 2011
Status verified
Feb 2018
Primary completion
Dec 28, 2015
Completion
Dec 28, 2015

Study Design

Enrollment
4,121 participants (actual)

Arms

  • Arm: Liraglutide

Primary Outcome Measure

The incidence of SADRs (Serious Adverse Drug Reactions) [ Time Frame: After 36 months ]

Related Studies